Dynamic and Rapid Isocratic Greener Analytical Method for Estimation of Chlorocresol along with Azole Compounds in Ointment

N.K. DHIR¹, D. CHAKRABORTY² and V. KAUR^{1,*}

¹Department of Chemistry, Chandigarh University, Gharuan, Mohali-140 413, India

²Department of Chemistry, Oxford College of Science, Bangalore-560 102, India

*Corresponding author: E-mail: dean.apc@cumail.in

Received: 21 August 2017;

Accepted: 4 October 2017;

Published online: 30 November 2017;

AJC-18676

The present work describes greener analytical method for the estimation of chlorocresol along with azole compounds, which are used in the manufacturing of derma products. Method is optimized and validated for chlorocresol and miconazole nitrate, clotrimazole taken for identification. Dynamic separation and identification is achieved between 0.69 to 3 min by UPLC method. The UPLC method was validated using an UPLC (BEH RP C18) column with a particle size of 1.7 μ (50 mm $\times$ 2.1 mm) and methanol-buffer (60:40, v/v) as mobile phase by setting the flow rate of 0.4 mL/min with isocratic elution. Degradation pathway was optimized and evaluated through PDA and unspecified degradation product from chlorocresol was predicted by Waters Acquity UPLC with Xevo TQD triple quad mass spectrometer from Waters. The UPLC method is shortest time consuming run, suitable for quantifications within good manufacturing practices of the pharma industry and the method is validated according to ICH guidelines.

Keywords: UPLC, Greener, Degradation, Validation, TQD/MS/MS.

INTRODUCTION

In pharmaceuticals manufacturing, several drug azoles are used as antifungal agents in the form of ointment and cream. These major azoles compounds are miconazole nitrate and clotrimazole whereas chlorocresol is a chlorinated phenol, which is used as an antiseptic and preservative during the formulation of these antifungal ointment and cream. These formulations are checked for the potency by validated analytical methods used by the industry. Several HPLC methods, spectroscopy techniques and titration methods are available to estimate these drugs before product release to market, so as to comply with the regulatory authority and for the patient safety [1,2]. Methods like RP-HPLC analysis used for the quantification are time consuming and take more time for final product release, which affects the supply chain and end user requirement [3-5]. The present research describes the time efficient method, which can help industry to release the product in shorter time and moreover it decreases the usage of solvents, which is in accordance with green chemistry concept [4]. Chlorocresol method development and analytical validation is a real challenge in the overall study due to low concentration used in formulations about 0.1 % w/w which is more sensitive towards gas chromatography analysis. As per pharmacopeia monograph chlorocresol is estimated by gas chromatography for the assay and related

substances [5,6]. In the present work, the method is designed to elute chlorocresol by UPLC with shortest run time in finished product where no official monograph is available for the estimation of miconazole, chlorocresol and clotrimazole in UPLC. During this method development activity, other azoles were optimized by this method along with the known impurity from clotrimazole, which involve 2-chlorotritanol. Forced degradation steps are optimized and applied to miconazole nitrate and chlorocresol and found to be well separated from each other under chromatographic conditions within very short span of time. This newly developed analytical method will not only reduce the analytical cost but also taken care of environmental safety aspect by reducing solvent consumption to comply EHS standard and EPA compliances [7]. An overview of the compounds used in the present study discussed below:

Chlorocresol is phenol based chlorinated molecule used as preservative as well as antiseptic for the manufacturing of antifungal creams and ointments. It is a slightly water soluble, dimorphous crystals at room temperature and colourless molecule [8]. Miconazole is synthetic imidazol derivative used as antifungal agent in ointment and cream formulations. It is soluble in dimethyl formamide, dimethyl sulfoxide and slightly soluble in methanol and water [9]. Clotrimazole drug molecule is used for treatment fungal infections as well as other disease like malaria, sickle cell anaemia, beriberi and cancer. It is

crystalline, lipophilic molecule having 0.49 g/L solubility in water [10].

The aim of the current study is to reveal the applicability of UPLC to develop, validate an UPLC/UV method to determine the assay for both miconazole nitrate (as an antifungal) and chlorocresol (as an antimicrobial preservative) in the ointment in support to quality control batch release and can also be used for process validation activity for ointment formulation plant.

EXPERIMENTAL

Methanol HPLC Grade, orthophosphoric acid (AR grade) and triethyl amine used as a modifier were purchased from Merck (Germany). Water was prepared freshly using a Milli-Q® equipment (Millipore). The reference materials are used as RS USP (United States Pharmacopeia) their purity used 99.40 % for reference standard. Waters UPLC® BEH RP C18 column with a particle size of 1.7 µ (50 mm × 2.1 mm) was purchased from Waters Ltd. Ireland 0.22 µ filter was purchased by Millipore Buffer is a mixture of composition of 0.1 % of orthophosphoric acid and 0.1 % of triethyl amine.

Equipment: Throughout the measurements and quantifications, Waters Acquity UPLC® H class with TUV system with Xevo TQD triple quad Mass spectrophotometer, Empower software from Waters Ltd MILFORD, MA01757 USA was employed. Solvent optimization was Quaternary System Manager (QSM) Controlled by Empower Software.

Chromatographic conditions: The mobile phases were prepared by mixing appropriate amount of UPLC grade methanol and buffer (0.1 % of orthophosphoric acid and 0.1 % triethylamine in 1000 mL of Milli-Q water). The mixtures were degassed by sonication for 5 min. The stock solutions of reference standards miconazole and chlorocresol [5,6] were used for standard run UPLC method parameters was set at given in Table-1.

TABLE-1
REPRESENTS THE CHROMATOGRAPHY
CONDITION FOR UPLC SEPARATION

Parameters	Conditions
Column used for separation	BEH Shield RP-18 (50×2.1 cm) 1.7 µm
Column temperature	40 °C
Wavelength	220 nm
Flow rate	0.4 mL/min
Injection volume	1 µL
Run time	About 3 min
Mobile phase	Buffer:Methanol (40:60)-Isocratic

Mobile phase preparation: Buffer solution was prepared by adding 1 mL of orthophosphoric acid and 1 mL of triethyl amine were mixed in 1000 mL of Milli-Q water. For the preparation of mobile phase 400 mL of buffer solution and 600 mL of methanol was added to prepare 1000 mL of mobile phase. It was mixed well and filtered through 0.2 µ filter.

Method validation approach

Standard validation stocks: Chlorocresol and miconazole nitrate was explored for method validation studies which include specificity, linearity accuracy, Precision, robustness and solution stability as per ICHQ2 guidelines [11].

Stock solution 1: 200 mg of miconazole nitrate as reference standard (RS) was taken in 100 mL volumetric flask which was dissolved in 75 mL mobile phase and sonicate for 5 min. Then, it was diluted to 100 mL with mobile phase.

Stock solution 2: 50 mg of chlorocresol (RS) was taken in 100 mL volumetric flask and dissolved in 75 mL mobile phase and sonicated for 5 min. It was then diluted it 100 mL with mobile phase.

Working standard solution: Working solution of miconazole of 200 ppm and chlorocresol of 50 ppm concentration was prepared from stock solution 1 and 2, respectively in mobile phase.

Test sample preparation: 2 g (wt.) of sample was taken in 200 mL volumetric flask and added 150 mL of mobile phase and sonicated for 20 min. The solution was heated in a water bath at 40 to 45 °C for 10 min by intermediate shaking. The solution was cooled to room temperature and the final volume of 200 mL was made with mobile phase, which is subjected for sonication for 20 min. It was mixed well and a portion of the solution was passed through 0.2 µm syringe filter into an UPLC vial.

System suitability evaluation: The working standard solution was injected six times and the calculated RSD should be < 2 %.

Assay of miconazole and chlorocresol: Equal volume of 1 µL each of standard, degradation samples and test sample preparation was injected into UPLC for analysis. The chromatograms were recorded and the responses were measured for the major peaks. Degradation summary were evaluated through PDA detector and relevant spectral information, purity was estimated accordingly for azole and chlorocresol.

Mass characterization for chlorocresol degradation impurity profiling: As per pharmacopeia monograph the chlorocresol is estimated through titrimetry methods and the related substances are estimated through gas chromatography [5,6]. The present method is a novel invention for identification of drug substances and its impurity and the process is sustained to the green chemistry principles by reducing solvent usage avoiding gas chromatography in the application of chlorocresol in pharmaceutical industries. The impurities were separated through UPLC after degradation of chlorocresol, which were screened through MS/MS.

Procedure for degradation of chlorocresol: 4-Chlorocresol (2.5 g, 0.0175 mol) was taken in 25 mL methanol and diluted up to 100 mL with 0.2 N HCl. The mixture was refluxed for 8-10 h at 80 °C on water bath. Degraded sample was then cooled to room temperature and neutralized with 0.2 N NaOH to pH 7.0. Suitable aliquot (1-2 mL) of this degraded reaction mixture was withdrawn and labelled as sample 1. Remaining solution was then evaporated on a water bath to remove methanol. The reaction mixture was taken in a separating funnel and extracted with chloroform (100 mL). After extraction the aqueous layer was collected and labelled as sample 2. The organic (chloroform) layer was evaporated to dryness and dissolved in methanol (10 mL) and labelled as sample 3. Chromatographic study shows that there is a formation of impurity around RT 5.015.

Pure chlorocresol along with sample 1, 2 and 3 were subjected to UPLC and the impurities were identified from UPLC

TABLE-2
REPRESENTS RETURN ON INVESTMENT (UPLC)

Elements	Traditional HPLC method	Current UPLC method	Comments
Run time	15 min/injection	3 min/injection	In current UPLC method, run time is ~5 times shorter
Flow rate	1.5 mL/min	0.4 mL/min	In current UPLC method, flow rate is ~3.7 times shorter
Solvent requirement	315 mL/sample	20 mL/sample	In current UPLC method, there is ~16 times reduction in solvent usage

chromatogram and the compound were characterized through Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) LC/MS analysis.

Miconazole nitrate was subjected to oxidation degradation and no other degradation studies were conducted for the same as reported by Abou-Elkheir *et al.* [12] showed that no degradation was found under acidic, alkaline and thermal degradation conditions for miconazole nitrate.

RESULTS AND DISCUSSION

Comparison of HPLC and UPLC for miconazole and chlorocresol: Fig. 1(a) represents HPLC chromatogram where the run time was 15 min and elution of standard miconazole eluted at 1.76 and for chlorocresol it was 8.407 min. The same standard of miconazole and chlorocresol was run in UPLC, which shows significant improvement in overall five time reduction in experimental time showed in Fig. 1(b). Table-2 represents overall ROI of UPLC in comparison with HPLC.

Fig. 1. (a) and (b) represents HPLC chromatogram of chlorocresol and miconazole nitrate by HPLC-run time 15 min and by UPLC-run time 3 min, respectively

Method validation outcome

Specificity: Fig. 2(a) and 2(b) demonstrate the specificity of method by identification of miconazole, clotrimazole and chlorocresol, which was separated from each other having no interference due to blank and placebo peak. Table-3 showed PDA results where all peak purity complies with the result and co-elution is obtained throughout the experiments.

Fig. 2. (a) and (b) represent the UPLC chromatogram and 3D spectrum overview

TABLE-3
REPRESENTS THE PEAK PURITY

Name	RT	Purity 1 angle	Purity 1 threshold	Purity flag
Nitrate	0.360	2.271	90.000	No
Clotrimazole	0.693	4.602	90.000	No
Chlorocresol	1.226	0.615	24.055	No
Miconazole	1.892	10.289	90.000	No

Linearity of response: Linearity of chlorocresol and miconazole has been access at the concentration range 80 to 120 % shown in Fig. 3(a) and 3(b), respectively, which was depicted by linear regression analysis revealed correlation coefficients, $r^2 = 0.999$.

Accuracy: Accuracy analysis (Tables 4 and 5) indicates the RSD percent recovery is 0.41 to 0.96 for chlorocresol and miconazole, respectively and both are within the acceptance limit.

Precision: System, method precision and intermediate precision were checked and found in within acceptable RSD < 2 %.

Fig. 3a. Linearity optimization for chlorocresol from 80 to 120 % concentration

Fig. 3b. Linearity optimization for miconazole from 80 to 120 % concentration

TABLE-4
REPRESENTS ACCURACY DATA OF CHLOROCRESOL

Chlorocresol recovery (%)					
Nominal (%)	Recovery (%)	Differenece	Results	Std. deviation	RSD
80	80.9	0.9	101.1	0.557	0.55
	80.3	0.3	100.4		
	80.0	0	100.0		
100	100.5	0.5	100.5	0.252	0.25
	100.3	0.3	100.3		
	100.0	0	100.0		
120	120.3	0.3	100.3	0.379	0.38
	120.3	0.3	100.3		
	119.6	0.4	99.7		
Avg			100.4		
Std. deviation			0.968		
RSD			0.41		

Robustness: Method was challenged by variation in flow rates, temperature and strength of solvent in mobile phase $\pm 10\%$. Table-6 revealed that the assay percentage is within the acceptance range where RSD is $< 2\%$.

Stability of analytical solution: The results are shown in Table-7 for the chlorocresol and miconazole sample stable

TABLE-6
DEPICTS ROBUSTNESS OF CHLOROCRESOL AND MICONAZOLE

Parameter		Retention time (min)		Assay (%)	
		Chlorocresol	Miconazole	Chlorocresol	Miconazole
Change in flow rate (0.4 mL/min $\pm$ 0.05 mL/min)	0.36 mL/min	1.17	1.37	97.7	103.5
	0.44 mL/min	0.91	1.27	97.2	104.4
Column temperature	36 °C	1.04	1.47	97.2	102.7
	44 °C	0.96	1.32	97.3	103.5
Mobile phase	-10 %	0.81	0.93	98.7	101.0
	+10 %	1.18	1.86	100.6	102.1
RSD for assay (%)				1.37	1.17

TABLE-7
STABILITY OF ANALYTICAL SOLUTION OF CHLOROCRESOL AND MICONAZOLE

Time	Chlorocresol				Miconazole			
	Initial results	After 24 h	After 48 h	RSD	Initial results	After 24 h	After 48 h	Difference
	100.5	98.7	98.5	1.11	101.8	102.8	100.3	1.24

TABLE-9
REPRESENTS ESI NEGATIVE ION MODE DATA

Sample	m/z	Daughters	Daughters	Daughters	Daughters	Daughters	Daughters	Daughters
Pure sample	141	63	71	77	105			
Sample 1	221	71	77	105	121	134	147	177
	141	63	71	77	105			
Sample 2	221	71	77	105	121	134	147	177
	141	63	71	77	105			
Sample 3	221	71	77	105	121	134	147	177
	141	63	71	77	105			

TABLE-5
REPRESENTS ACCURACY DATA OF MICONAZOLE

Miconazole recovery (%)					
Nominal (%)	Recovery (%)	Differenece	Results	Std. deviation	RSD
80	81.4	1.4	101.7	0.265	0.26
	81.3	1.3	101.6		
	81.0	1	101.2		
100	99.5	0.5	99.5	0.20	0.20
	99.3	0.7	99.3		
	99.1	0.9	99.1		
120	120.4	0.4	100.4	0.058	0.06
	120.4	0.4	100.4		
	120.4	0.4	100.3		
Avg			100.4		
Std. deviation			0.968		
RSD			0.96		

upto 48 h at room temperature within the acceptance not more than 2 % RSD.

Filter variability: Result obtained in Table-8 shows difference not more than 1.5 %, which is within the acceptance range and it does not affect the results.

MS/MS outcome: Table-9 depicts the ESI negative ion mode data. Impurities shown same fragments of parent m/z 141

TABLE-8
REPRESENTS FILTER VARIABILITY OF CHLOROCRESOL AND MICONAZOLE FOR UPLC

Content	Membrane filter (%)	Nylon filter (%)	Difference (%)
Miconazole	100.7	101.0	0.3
Chlorocresol	97.0	98.5	1.5

and m/z 221 having daughters 71, 77 and 105 shows structural similarity (Figs. 4 and 5). In positive mode m/z 212 and 223 was seen in all three impurities and m/z 212 and 223 share common fragment in all samples represented in Table-10 (Figs.

6 and 7). m/z 237, 277 and 295 additionally seen in sample 3 which has the same fragments as m/z 223 in positive ion mode shown in Table-10. Fig. 8 corresponds to predicted structure of unspecified impurity obtained from degradation of chlorocresol.

TABLE-10 REPRESENTS ESI POSITIVE ION MODE DATA							
Sample	m/z	Daughters	Daughters	Daughters	Daughters	Daughters	Daughters
Sample 1	212	136	168	194	—	—	—
	—	57	149	—	—	—	—
Sample 2	212	92	109	124	136	168	194
	223	57	149	—	—	—	—
Sample 3	223	57	149	—	—	—	—
	237	57	149	163	205	—	—
	277	57	149	161	175	203	—
	295	—	149	—	175	203	—
	317	114	254	261	—	—	—

Fig. 4. Fragmentation interpretation of 141 in negative ion mode

Fig. 5. Fragmentation interpretation of 221 in negative ion mode

Fig. 6. Fragmentation interpretations of 212 in positive ion mode

Fig. 7. Probable elemental composition predicted in positive ion mode for 223

Conclusion

On the basis of this study, it appears that the use of this currently developed UPLC method for the quantification of miconazole (or clotrimazole) and chlorocresol in antifungal ointment and cream is much faster and robust method as compare to HPLC analysis in product formulation area is practical. The time reduction and solvent saving characteristics of current UPLC method are very advantageous, compared to the most widely used conventional HPLC technique. The enhanced sensitivity of the UPLC-UV method compared to conventional HPLC does not necessitate the use of a mass spectrometry detector, which is expensive. The concept of applying this generic method for several API is feasible and practical if the structure and properties of compounds to be determined are of similar type.

Structure A

Fig. 8. Represented unspecified predicted impurity; m.f.: C₁₄H₁₉Cl; exact mass: 222.12; m.w. 222.75; Elemental composition: C, 75.49; H, 8.60; Cl, 15.92

REFERENCES

1. N.J. Dhir and S.K. Yadav, *J. Indian Chem. Soc.*, **89**, 1665 (2012).
2. N. Dhir, D. Chakraborty and V. Kaur, Patent filing number: 4299/DEL/2015.
3. S.E. Johnston, N.L. Gill, Y.C. Wei, R. Markovich and A.M. Rustum, *J. Chromatogr. Sci.*, **48**, 733 (2010); <https://doi.org/10.1093/chromsci/48.9.733>.
4. N. O'Connor, M. Geary, M. Wharton and P. Sweetman, *J. Chromatogr. Sci.*, **50**, 199 (2012); <https://doi.org/10.1093/chromsci/bmr047>.
5. European Pharmacopeia, version 8, vol. 2 (2015).
6. British Pharmacopeia, version 8, vol. 1, p. 519 (2015).
7. P.J. Dunn, A. Wells and M.T. Williams, *Green Chemistry in the Pharmaceutical Industry*, Wiley-VCH Verlag GmbH & Co (2010).
8. *p*-Chloro-*m*-cresol [MAK Value Documentation, 1991]. The MAK Collection for Occupational Health and Safety, 272 (2012).
9. A.A. Al-Badr, *Profiles Drug Subst. Excip. Relat. Methodol.*, **32**, 3 (2005); [https://doi.org/10.1016/S0099-5428\(05\)32007-7](https://doi.org/10.1016/S0099-5428(05)32007-7).
10. S. Kadavakollu, C. Stailey, C.S. Kunapareddy and S. White, *Med. Chem. (Los Angeles)*, **4**, 722 (2014); <https://doi.org/10.4172/2161-0444.1000219>.
11. ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Methodology (1996).
12. A. Abou-elkheir, H.M. Saleh, M. Magda, B.S. Ghareeb and M.S. Mohram, *Indo-Am. J. Pharm. Sci.*, **5**, 641 (2015).